The test is compatible with lateral flow technology and could be used to provide tuberculosis testing in low-resource settings.

The firm said it is in talks with payors about pilot programs and it expects to soon publish data on the use of its test to improve outcomes and reduce healthcare costs.

The Johns Hopkins University spinout's MycoMeia Aspergillus Assay is used to aid the diagnosis of the lung disease aspergillosis in immunocompromised patients.

The company also announced it would be divesting its Exosome Diagnostics business and selling it to MDxHealth.

The firm saw an increase in diagnostics solutions sales in the second quarter, particularly within its QuantiFeron and QiaStat-Dx businesses.

The firm anticipates lower-than-previously-expected COVID test sales will be offset by shifts in trade policy and tariff mitigation efforts.

As part of the deal, the company is acquiring a "significant library of potential applications" of the test's exosome-based technology.

Stakeholders suggested that while the FDA rule is dead, updates to LDT regulation are coming, nonetheless, and the industry ...

Danaher subsidiaries Beckman Coulter, Cepheid, and Leica Biosystems will be working together with external partners to focus ...

The South Korean firm said that its CURECA system offers walkaway PCR testing with 24/7 operation without human intervention ...

Through clinical trials, partnerships, and economic studies, a crop of test developers is trying to prove the value of their ...

China's volume-based procurement policy and US tariffs have forced companies with large businesses in China to reset their ...